FDA gives combo blood pressure tablet green light

Candace Stuart | | Cardiovascular Business | Patient Care

The FDA approved a pill that combines a calcium channel blocker and an ACE inhibitor as a treatment for hypertension.

The approved tablets combine perindopril arginine and amlodipine under the brand name Prestalia (Symplmed Pharmaceuticals). The fixed-dose tablets are designed to reduce diastolic and systolic blood pressure in patients whose hypertension is not adequately treated by a single therapy. The combination pill also can be prescribed for patients whose physicians conclude likely will need several drugs to meet their blood pressure targets.

Cincinnati-based Symplmed Pharmaceuticals licenses Prestalia from the French company Servier. Symplmed plans to make the tablets available in the U.S. in the first quarter of 2015.

 

Candace Stuart, Contributor

Related Content

Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
FDA approves Medtronic’s new all-in-one mapping and ablation system for AFib

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."